Get the Stockscreener App
7.27
6.44%
-0.50
After Hours:
7.40
0.13
+1.79%
Arcturus Therapeutics Holdings Inc stock is traded at $7.27, with a volume of 1.13M.
It is down -6.44% in the last 24 hours and down -65.79% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
See More
Previous Close:
$7.77
Open:
$7.44
24h Volume:
1.13M
Relative Volume:
0.94
Market Cap:
$197.41M
Revenue:
$157.75M
Net Income/Loss:
$-29.73M
P/E Ratio:
-6.2672
EPS:
-1.16
Net Cash Flow:
$-21.00M
1W Performance:
-16.63%
1M Performance:
-65.79%
6M Performance:
-32.93%
1Y Performance:
-60.36%
1-Day Range:
$7.26
$7.65
1-Week Range:
$7.26
$9.29
52-Week Range:
$7.26
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
7.27 | 220.77M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-23-25 | Downgrade | Citigroup | Buy → Neutral |
| Oct-22-25 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-28-25 | Initiated | BTIG Research | Buy |
| Aug-12-24 | Initiated | Leerink Partners | Outperform |
| Dec-13-23 | Initiated | Canaccord Genuity | Buy |
| Jul-24-23 | Initiated | William Blair | Outperform |
| May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-14-22 | Resumed | Wells Fargo | Overweight |
| Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
| May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
| Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
| Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-07-21 | Initiated | Wells Fargo | Overweight |
| Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
| Dec-08-20 | Reiterated | B. Riley Securities | Buy |
| Dec-07-20 | Reiterated | B. Riley Securities | Buy |
| Oct-26-20 | Initiated | Barclays | Overweight |
| Oct-06-20 | Initiated | Citigroup | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-30-20 | Resumed | ROTH Capital | Buy |
| Jul-16-20 | Initiated | Raymond James | Outperform |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
| Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Apr-05-19 | Initiated | H.C. Wainwright | Buy |
| Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
Published on: 2025-11-15 17:06:19 - newser.com
Can momentum traders help lift Arcturus Therapeutics Holdings Inc.Gold Moves & Detailed Earnings Play Alerts - newser.com
What technical models suggest about Arcturus Therapeutics Holdings Inc.’s comeback2025 Market Outlook & Momentum Based Trading Signals - newser.com
Arcturus Therapeutics Holdings Inc. stock volume spike explained2025 EndofYear Setup & High Accuracy Trade Alerts - newser.com
How to forecast Arcturus Therapeutics Holdings Inc. trends using time seriesJuly 2025 Market Mood & Technical Pattern Recognition Alerts - newser.com
Can Arcturus Therapeutics Holdings Inc. stock beat market expectations this quarter2025 Investor Takeaways & Verified Momentum Stock Alerts - newser.com
Arcturus Therapeutics Hits New 52-Week Low at $7.76 - Markets Mojo
What is William Blair’s Forecast for ARCT FY2025 Earnings? - Defense World
Published on: 2025-11-13 18:13:53 - newser.com
How to use a screener to detect Arcturus Therapeutics Holdings Inc. breakoutsJuly 2025 Recap & Precise Swing Trade Alerts - newser.com
Citigroup Maintains Arcturus Therapeutics Holdings (ARCT) Neutral Recommendation - Nasdaq
Arcturus outlines 12-week cystic fibrosis study launch in 2026 amid cost controls and delayed KOSTAIVE BLA - MSN
ARCT: Citigroup Adjusts Price Target and Maintains Neutral Ratin - GuruFocus
Is Arcturus Therapeutics Holdings Inc. stock cheap at current valuation2025 Technical Patterns & Real-Time Volume Analysis Alerts - newser.com
What MACD signals say about Arcturus Therapeutics Holdings Inc.Rate Hike & AI Powered Buy and Sell Recommendations - newser.com
How currency fluctuations impact Arcturus Therapeutics Holdings Inc. stockOil Prices & Weekly Top Gainers Trade List - newser.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2025 Earnings Call Transcript - Insider Monkey
Arcturus Therapeutics Holdings Inc. SEC 10-Q Report - TradingView
ARCT: HC Wainwright & Co. Lowers Price Target, Maintains Neutral Rating | ARCT Stock News - GuruFocus
Understanding the Setup: (ARCT) and Scalable Risk - news.stocktradersdaily.com
HC Wainwright & Co. Maintains Arcturus Therapeutics Holdings (ARCT) Neutral Recommendation - Nasdaq
Arcturus Therapeutics (ARCT) Target Price Significantly Lowered by Piper Sandler | ARCT Stock News - GuruFocus
Arcturus Therapeutics Holdings Inc earnings missed by $6.02, revenue fell short of estimates - Investing.com Australia
Published on: 2025-11-11 06:27:18 - newser.com
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates - sharewise.com
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2025 Earnings Call Highlights: Navigating ... By GuruFocus - Investing.com Canada
Arcturus Therapeutics (ARCT) Reports Q3 2025 Earnings and Clinical Updates - GuruFocus
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2025 Earnings Call Highlights: Navigating ... - Yahoo Finance
Arcturus Therapeutics Reports Q3 2025 Financials and Pipeline Progress - TipRanks
What analysts say about Arcturus Therapeutics Holdings Inc stockStock Market Trends & Low Entry Investment Portfolio - earlytimes.in
Earnings call transcript: Arcturus Therapeutics’ Q3 2025 Earnings Miss Expectations - Investing.com
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress - BioSpace
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm - The Malaysian Reserve
Earnings call transcript: Arcturus Therapeutics’ Q3 2025 Earnings Miss Expectations By Investing.com - Investing.com UK
Arcturus Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Arcturus Therapeutics (ARCT) Exceeds Q3 Revenue Expectations - GuruFocus
Arcturus Therapeutics: Q3 Earnings Snapshot - MarketScreener
What candlestick patterns are forming on Arcturus Therapeutics Holdings Inc.Market Movers & Safe Entry Point Alerts - newser.com
Arcturus Therapeutics Hits 52-Week Low at $7.93 Amid Financial Struggles - Markets Mojo
What is Arcturus Therapeutics Holdings Inc (ARCT) Stock Return on Shareholders’ Capital? - setenews.com
Is Arcturus Therapeutics Holdings Inc. stock ready for a breakoutGlobal Markets & Technical Buy Zone Confirmations - newser.com
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):